Clinical trials: Eyes With Retinal Diseases
Geographic Atrophy
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT05626114
- Testing
- OpRegen
- Where
- 17 sites in United States, Israel
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
LCA5
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration…
- Trial name
- NCT05616793
- Testing
- AAV8.hLCA5
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Opus Genetics, Inc
Cytomegalovirus Retinitis, HIV Infections
A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)
To assess the relative efficacy of oral versus intravenous hydration during foscarnet sodium (Foscavir) induction therapy, as determined by changes in creatinine clearance.
- Trial name
- NCT00002125
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astra USA
Macular Degeneration
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
- Trial name
- ARIES (NCT02581891)
- Testing
- Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 39 sites in Australia, Canada and 6 more
- Volunteers
- 287 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Geographic Atrophy
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD, Non-neovascular Age-related Macular Degeneration
- Trial name
- JOURNEY (NCT06087458)
- Testing
- VOY-101
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Macular Degeneration
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
- Trial name
- CEDAR (NCT02462928)
- Testing
- Abicipar Pegol, Ranibizumab
- Where
- 151 sites in United States, Argentina and 15 more
- Volunteers
- 939 people
- Sponsor
- Allergan
Cytomegalovirus Retinitis, HIV Infections
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune adjuvant in HIV-seropositive patients.
- Trial name
- NCT00002321
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis
Leber Congenital Amaurosis 10, Blindness
Extension Study to Study PQ-110-001 (NCT03140969)
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- INSIGHT (NCT03913130)
- Testing
- QR-110
- Where
- 3 sites in United States, Belgium
- Volunteers
- 9 people
- Sponsor
- Laboratoires Thea
Leber Congenital Amaurosis (LCA), Eye Diseases
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
This study is a longer-term follow-up study for patients who have been administered AAV2/5-OPTIRPE65 in the Phase I/II, open label, non-randomised, two-centre, dose escalation trial in adults and children with retinal dystrophy…
- Conditions
- Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
- Trial name
- NCT02946879
- Testing
- AAV OPTIRPE65
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- MeiraGTx UK II Ltd
Geographic Atrophy, Macular Degeneration
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a…
- Trial name
- NCT06779773
- Testing
- Avacincaptad pegol (ACP)
- Where
- 58 sites in United States
- Volunteers
- 488 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past.
- Trial name
- NCT00002222
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Retinitis Pigmentosa
Development of Visual Function Evaluation Method
The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient
- Trial name
- NCT03281005
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Macular Edema, Central Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Trial name
- COMINO (NCT04740931)
- Testing
- Faricimab, Aflibercept
- Where
- 194 sites in United States, Argentina and 20 more
- Volunteers
- 729 people
- Sponsor
- Hoffmann-La Roche
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C.
- Conditions
- Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
- Trial name
- NCT03888716
- Testing
- KL1333
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Abliva AB
Neovascular Age-Related Macular Degeneration (nAMD)
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up…
- Trial name
- SHASTA (NCT04746963)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Age-related Macular Degeneration
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related…
- Trial name
- SUSHI (NCT03633084)
- Testing
- RBM-007 Injectable Solution
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Ribomic USA Inc
Macular Edema, Radiation Retinopathy
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.
- Conditions
- Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane
- Trial name
- NCT04120311
- Testing
- Episcleral Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Targeted Therapy Technologies, LLC
Age Related Macular Degeneration (AMD)
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
The aim of this study is to test if PF582 (ranibizumab) is safe and similar to Lucentis (ranibizumab). Participants will have a screening visit to check for eligibility.
- Trial name
- NCT02121353
- Testing
- Lucentis, PF582
- Where
- 2 sites in New Zealand
- Volunteers
- 25 people
- Sponsor
- Pfenex, Inc